DYRK1A and Dravet syndrome: Additional novel DYRK1A inhibitors have been identified that can induce DYRK1A degradation that can be useful for decreasing the dosage of the expressed protein in AD and DS, but further research is required to evaluate their potential for therapeutic use (Branca et al., 2017; Melchior et al., 2019; Velazquez et al., 2019).